Studies and clinical observation show individuals with significant weight loss can appear as much as five years older than same-age peers who maintain their weight
Sports medicine physician Dr
11 , 1522 (2004) Koth, C
Retatrutide is not yet FDA approved, but like many GLP-1 agonists such as Wegovy (semaglutide) and Mounjaro (tirzepatide), retatrutide will most likely be a weekly injection, delivered subcutaneously into the arm, thigh or stomach area in a self-inject pen
Each passing week witnesses the unveiling of new multi-million-dollar investments, propelling GLP-1 players to the forefront of pharmaceutical revenue growth
Providers should monitor weight trajectory , GI tolerability (nausea, vomiting, constipation) , signs of pancreatitis (persistent severe abdominal pain vomiting), gallbladder disease (RUQ pain, fever, jaundice), hydration/renal function when clinically indicated (risk of AKI with severe GI effects), blood pressure , and glucose metrics (especially if combined with insulin or sulfonylureas due to hypoglycemia risk)
)
